SCHEDULE 13G: Guernsey Entities Disclose Significant 9.98% Stake in Conduit Pharmaceuticals Inc.
Beneficial Ownership Disclosure
Nirland Limited and related Guernsey-based entities have disclosed a beneficial ownership of 9.979% in Conduit Pharmaceuticals Inc., stemming from the conversion of a Senior Secured Promissory Note.
Summary
- Nirland Limited, Stockton Limited, The Rowland Master Trust, and Dovet Limited, all registered in Guernsey, have jointly filed a Schedule 13G disclosing their beneficial ownership in Conduit Pharmaceuticals Inc.
- The reporting persons collectively beneficially own 15,350,000 shares of Conduit Pharmaceuticals Inc. Common Stock.
- This ownership represents 9.979% of the company's outstanding Common Stock, based on 153,830,170 shares outstanding as of January 10, 2025.
- The shares were acquired upon conversion of a Senior Secured Promissory Note, dated August 6, 2024, as amended, entered into by Conduit Pharmaceuticals Inc. and Nirland Limited.
- The Nirland Note allows for conversion of up to 75,000,000 shares of Common Stock, subject to a blocker preventing the reporting person from beneficially owning more than 9.99% of outstanding shares after conversion.
- Nirland Limited is wholly owned by Stockton Limited, which is wholly owned by The Rowland Master Trust, and Dovet Limited is the sole trustee of The Rowland Master Trust, establishing shared beneficial ownership among these entities.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance, though a significant stake by an investor can be interpreted positively by some.
Positives
- The disclosure of a significant stake by institutional entities may signal confidence in Conduit Pharmaceuticals Inc. from these investors.
Risks
- The Senior Secured Promissory Note allows for conversion of up to 75,000,000 shares, which, if fully converted (subject to the 9.99% blocker), could lead to significant future dilution for existing shareholders.
- The existence of a 9.99% conversion blocker limits the immediate ability of the reporting persons to convert more shares, potentially impacting their liquidity or strategic flexibility.
Future Outlook
This document is a beneficial ownership disclosure and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This filing indicates a significant ownership stake by a group of related entities in a pharmaceutical company, which is a common occurrence in the industry as companies seek financing for research and development. The conversion of a promissory note into equity is a typical financing mechanism.
Related Party Transactions
- Nirland Limited, Stockton Limited, The Rowland Master Trust, and Dovet Limited are related parties through ownership and trustee relationships, and have entered into a Joint Filing Agreement for this Schedule 13G.
- The acquisition of shares by Nirland Limited is a result of the conversion of a Senior Secured Promissory Note with Conduit Pharmaceuticals Inc.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a group of investors may be viewed as a vote of confidence. However, the potential for further conversion of the promissory note into equity could lead to future dilution.
- Creditors: The conversion of a secured promissory note into equity reduces the company's debt obligations to the extent of the conversion, potentially improving its balance sheet.
Key Dates
| Date | Description |
|---|---|
| 2024-08-06 | Date of the Senior Secured Promissory Note entered into by Conduit Pharmaceuticals Inc. and Nirland Limited. |
| 2024-11-01 | Date of an amendment to the Senior Secured Promissory Note, filed as Exhibit 4.4 to the Issuer's Current Report on Form 8-K. |
| 2024-11-25 | Date of an amendment to the Senior Secured Promissory Note, filed as Exhibit 4.2 to the Issuer's Current Report on Form 8-K. |
| 2025-01-10 | Date as of which 153,830,170 shares of Common Stock were reported as issued and outstanding, used for percentage calculation. |
| 2025-01-13 | Date of event which requires filing of this statement (beneficial ownership exceeding 5%). |
| 2025-01-15 | Date of the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with Registration No. 333-282802. |
| 2025-01-21 | Date of the Joint Filing Agreement among the Reporting Persons and the filing date of this Schedule 13G. |
Keywords
Conduit Pharmaceuticals Inc., Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Promissory Note, Equity Stake, Guernsey, Nirland Limited, Stockton Limited, The Rowland Master Trust, Dovet Limited
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.